Verbatim response from Claude
This is a fast-moving situation, so I want to be straightforward with you:
What Happened
The FDA declared the semaglutide shortage over in early 2025, which legally requires most compounding pharmacies to stop making copies of Ozempic/Wegovy. Tirzepatide (Mounjaro/Zepbound) followed similarly.
Current Landscape (as of my knowledge)
Several platforms have had to discontinue or significantly restrict compounded GLP-1s:
- Hims & Hers - faced legal pressure, adjusted offerings
- Ro - modified their compound programs
- Henry Meds - navigating changes
What Some Still Offer (with caveats)
- Personalized/combination formulations may still be legally permissible in some cases
- Some platforms claim 503A pharmacy exemptions for individualized prescriptions
My Honest Recommendation
Rather than chasing compounded options that may be legally questionable:
- Sesame or Teladoc can connect you with providers for brand-name prescriptions with manufacturer savings programs
- Eli Lilly's LillyDirect offers Zepbound directly
- Novo Nordisk's savings cards can significantly reduce Wegovy costs
Important Caveat
This space changes weekly. I'd verify current offerings directly with any platform, and be cautious of services making claims that seem to skirt FDA rules.
Want help finding legitimate savings on brand-name options?